China-Italy Joint Laboratory of Pharmaceutical Biotechnology and Immunosafety Launched in Shenzhen
Guangzhou, The Gulf Observer: The China-Italy Joint Laboratory of Pharmaceutical Biotechnology and Immunosafety has officially launched in Shenzhen, Guangdong Province, marking a significant step towards promoting the international transformation of scientific and technological achievements in the biopharmaceutical sector.
The laboratory is a collaborative effort between the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences, the Institute of Biochemistry and Cell Biology, and the Institute of Translational Pharmacology, with the latter two institutions being part of the National Research Council (CNR) of Italy.
Focusing on two primary research directions, the laboratory will concentrate on the immunotoxicity evaluation of natural and artificial substances, alongside the study of their related pathogenic or toxic mechanisms. Additionally, the laboratory will work on developing immunomodulatory drugs and advancing strategies for disease prevention and immunotherapy, according to the laboratory’s director, Li Yang.
Xu Jianbin, Vice President of SIAT, highlighted that the establishment of the joint laboratory has further strengthened academic ties between China and Italy. He emphasized that it provides an outstanding platform for exploring bilateral cooperation in the biomedical field.
